RaQualia Pharma Inc. provided financial guidance for the fiscal year ending December 31, 2020. The company expected net sales of JPY 1,579 million, operating loss of JPY 260 million, loss attributable to owners of parent of JPY 333 million and loss per share basic of JPY 15.93.